

DAFTAR PUSTAKA

- Amalia A., Latief N., Murtala B., Zainuddin A.A., Daud N.A. (2020). Factors Affecting Tumor Response to Transarterial Chemoembolization (TACE) therapy in patient with Hepatocellular Carcinoma (HCC). *Journal of the Medical Sciences*,52,2,144-152.
- Anis, M., Irshad. (2011). Imaging of Hepatocellular Carcinoma : Practical Guide to Differential Diagnosis. *Clinics in Liver Disease*,15(2),pp.335-52. Available from : 10.1016/j.cld.2011.03.014
- Abou-Alfa,G. K., Meyer,T., Cheng,A.-L., El-Khoueiry,A.B., Rimassa,L., Ryoo,B.-Y., Cicin,I., et al. (2018). Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma. *New England Journal of Medicine*,379(1),pp.54–63. Available from : <https://doi.org/10.1056/NEJMoa1717002>
- Bruix J., and Sherman M. (2011). Management of Hepatocellular Carcinoma : An Update. *Hepatology*, 53(3), pp.1020-22. doi : 10.1002/hep.24199
- Basile A., Carrafiello G., Ierardi A.M., et al. (2012). Quality-Improvement Guidelines for Hepatic Transarterial Chemoembolization. *Cardiovascular and Interventional Radiological Society of Europe*,35, pp.765-74. doi : 10.1007/s00270-012-0423-z.
- Budjan,J., Sauter,E.A., Morelli,J.N., Nolden,M., Fetzer,A., Pilz,L., Reichert,M., et al. (2016). Semi-automatic Volumetric Measurement of Treatment Response in Hepatocellular Carcinoma After Trans-arterial Chemoembolization. *Anticancer Research*,36(8), pp.4353–4358.
- Cahyono, J.B.S.B. (2019). Tatalaksana Klinis di Bidang Gastro dan Hepatologi. *Sagung Seto*, 2, pp.837 - 40.
- Carr,B.I. (2011). Tumors of the liver and billiary tree. In : Kasper DL, Hauser SL, Jameson JL, Fauci AS, Longo DL, Loscalzo J, editor. *Harrison's principles of internal medicine*. New York:McGraw Hill,pp.544-50
- Claudon,M., Dietrich,C., Choi,B., Cosgrove,D., Kudo,M., Nolsøe,C., Piscaglia,F., et al. (2012). Guidelines and Good Clinical Practice Recommendations for

Contrast Enhanced Ultrasound (CEUS) in the Liver – Update 2012.
Ultraschall in Der Medizin - European Journal of Ultrasound, 34(01),
pp.11–29. Available from : <https://doi.org/10.1055/s-0032-1325499>

Cheng,A.-L., Kang,Y.-K., Chen,Z., Tsao,C.-J., Qin,S., Kim,J.S., Luo,R., et al.(2009). Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. *The Lancet Oncology*,10(1),25–34. Available from : [https://doi.org/10.1016/S1470-2045\(08\)70285-7](https://doi.org/10.1016/S1470-2045(08)70285-7)

Cheng,A.L, Amarapurkar,D., Chao,Y., Chen,P.J., Geschwind,J.F., Goh,K.L, Han K.H., et al. (2014). Re-evaluating Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma : Consensus Recommendations and Review by an International Expert Panel. *Liver International*,34,174-83. doi : 10.1111/liv.12314

Chen,I.-P., Ariizumi,S., Nakano,M., & Yamamoto,M. (2014). Positive glypican-3 expression in early hepatocellular carcinoma predicts recurrence after hepatectomy. *Journal of Gastroenterology*,49(1),117–125. Available from : <https://doi.org/10.1007/s00535-013-0793-2>

Dwinanda,A., Afriani,N., & Hardisman,H. (2019). Pengaruh Jus Seledri (*Apium graveolens* L.) terhadap Gambaran Mikroskopis Hepar Tikus (*Rattus norvegicus*) yang Diinduksi Diet Hiperkolesterol. *Jurnal Kesehatan Andalas*, 8(1), 68. Available from : <https://doi.org/10.25077/jka.v8i1.972>

Ellis H. (2011). Anatomy of the Liver. *Surgery*,29(12),1-4

El-Serag H.B., Marrero J.A., Rudolph L., et al. (2008). Diagnosis and Treatment of Hepatocellular Carcinoma. *Gastroenterology*, 134(6),1752-63. doi:10.1053/j.gastro.2008.02.090

Fan,J., Wu,Z.Q., Tang,Z.Y., Zhou,J., Qiu,S.J., Ma,Z.C., Zhou,X.D., et al. (2001). Multimodality Treatment in Hepatocellular Carcinoma Patients with Tumor Thrombi in Portal Vein. *World Journal of Gastroenterology*,7(1),pp.28-32. DOI: 10.3748/wjg.v7.i1.28

Fournier,L., Ammari,S., Thiam,R., Cuenod,C.A. (2014). Imaging Criteria for Assessing Tumour Response : RECIST, mRECIST, Cheson. *Diagnostic*

and Interventional Imaging. Elsevier Masson SAS,95:pp. 689-703.

Available from :

<https://reader.elsevier.com/reader/sd/pii/S2211568414001569?token=>

Georgiades,C., Geschwind,J.-F., Harrison,N., Hines-Peralta,A., Liapi,E., Hong,K., Wu,Z., et al. (2012). Lack of Response after Initial Chemoembolization for Hepatocellular Carcinoma: Does It Predict Failure of Subsequent Treatment?. *Radiology*,265(1),115–23. Available from : <https://doi.org/10.1148/radiol.12112264>

Han,K. & Kim,J.H. (2015). Transarterial Chemoembolization in Hepatocellular Carcinoma Treatment : Barcelona Clinic Liver Cancer Staging System. *World Journal of Gastroenterology*,21(36),10327-35. doi : [10.3748/wjg.v21.i36.10327](https://doi.org/10.3748/wjg.v21.i36.10327)

Hsu,CY., Lee,YH., Huang,YH., Hsia,CY., Su,CW., Lin,HC., Lee,RC., et al.(2013). Ascites in Patients with Hepatocellular Carcinoma : Prevalence, Associated Factors, Prognostic Impact, and Staging Strategy. *Hepatol Int*,7,pp.188-198. DOI 10.1007/s12072-011-9338-z

Hyun D., Shin S.W., Cho S.K., et al. (2015). Efficacy of RECIST and mRECIST criteria as prognostic factors in patients undergoing repeated iodized oil chemoembolization of intermediate stage hepatocellular carcinoma. *Acta Radiologica*, 56(12),1-9. doi : [10.1177/0284185114560937](https://doi.org/10.1177/0284185114560937)

Idee J.M., Guiu B. (2013). Use of Lipiodol as a Drug-Delivery System for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma : a Review. *Critical Reviews in Oncology/Hematology*, 88 (3),530-49. Available from : <http://dx.doi.org/10.1016/j.critrevonc.2013.07.003>

Jin,Z.C., Chen,L., Zhong,B.Y., et al. (2021). Impact of COVID-19 Pandemic on Intervals and Outcomes of Repeated Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma. *Frontiers in Oncology*, 11,1-8. Available from : <https://doi.org/10.3389/fonc.2021.602700>

Katayama,K., Imaia,T., Abea,Y., Nawaa,T., Maedab,N., Nakanishib,K., Wadac,H., et al. (2018). Number of Nodules but not Size of Hepatocellular Carcinoma Can Predict Refractoriness to Transarterial

Chemoembolization and Poor Prognosis. *J Clinic Med Res*,10(10),765-771.

Kelley,R.K., Verslype,C., Cohn,A.L., Yang,T.-S., Su,W.-C., Burris,H., Braiteh,F., et al. (2017). Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study. *Annals of Oncology*,28(3), 528–34. Available from : <https://doi.org/10.1093/annonc/mdw651>

Kikuchi, L., Chagas, A. L., Alencar, R. S. S. M., Tani, C., Diniz, M. A., D’Albuquerque, L. A. C., & Carrilho, F. J. (2017). Adherence to BCLC recommendations for the treatment of hepatocellular carcinoma: impact on survival according to stage. *Clinics*,72(8),454–460. [https://doi.org/10.6061/clinics/2017\(08\)01](https://doi.org/10.6061/clinics/2017(08)01)

Khorsandi S.E., Heaton N. (2012). Contemporary Strategies in the Management of Hepatocellular Carcinoma, *HPB Surgery*,2012,1-8. doi: 10.1155/2012/154056

Kotsifa,E., Vergadis,C., Vailas M. (2022). Transarterial Chemoembolization for Hepatocellular Carcinoma : Why, When, How ?. *Journal of Personalized Medicine*,12,436. doi: <https://doi.org/10.3390/jpm12030436>

Keputusan Menteri Kesehatan Republik Indonesia, Nomor HK.01.07/Menkes/1355/2022 tentang Pedoman Nasional Pelayanan Kedokteran Tata Laksana Karsinoma Sel Hati pada Dewasa, (2022). Available from : https://yankes.kemkes.go.id/unduh/fileunduhan_1664864202_179501.pdf

Kim T.M., Lee J.M., Yoon J.H., et al. (2020). Prediction of Microvascular Invasion of Hepatocellular Carcinoma : Value of Volumetric Iodine Quantification Using Preoperative Dual-Energy Computed Tomography. *Cancer Imaging*,20(60),1-11. Available from : <https://doi.org/10.1186/s40644-020-00338-7>

- Lee, I. J., Chun, H. J., & Chung, J. W. (2023). 2022 Korean Liver Cancer Association-National Cancer Center Korea Practice Guidelines for Transarterial Therapy of Hepatocellular Carcinoma: What's New?. *Korean Journal of Radiology*, 24(1), 6. <https://doi.org/10.3348/kjr.2022.0510>
- Llovet, J.M., Mas, X., Aponte, J.J., Fuster, J., Nasava, M., Christensen, E., Rodes, J., et al. (2002). Cost effectiveness of adjuvant therapy for hepatocellular carcinoma during the waiting list for liver transplantation. *Gut*, 50(1), 123–128. <https://doi.org/10.1136/gut.50.1.123>
- Lim M.C., Tan C.H., Cai J., et al. (2014) CT volumetry of the Liver : Where does it stand in Clinical Practice?. *Clinical Radiology*, e1-e9. Available from: <http://dx.doi.org/10.1016/j.crad.2013.12.021>
- Lv, W.F., Liu, K.C., Lu, D., Zhou, C.Z., Cheng, D.L., Xiao, J.K., Zhang, X.M., et al. (2018). Transarterial Chemoembolization for Hepatocellular Carcinoma Combined with Portal Vein Tumor Thrombosis. *Cancer Management and Research*, 10, 4719-26. Doi : 10.2147/CMAR.S166527
- Ma, Wenhui., Jia, Jia., Wang, Shengjun. (2014). The Prognostic Value of 18F-FDG PET/CT for Hepatocellular Carcinoma Treated with Transarterial Chemoembolization (TACE). *Theranostic*, 4(7), 736-744. doi: 10.7150/thno.8725
- Mahadevan, V. (2020). Anatomy of the liver. *Surgery (Oxford)*, 38(8), 427–431. Available from : <https://doi.org/10.1016/j.mpsur.2014.10.004>
- Marrero, J.A., Kulik, L.M., Sirlin, C.B., Zhu, A. X., Finn, R.S., Abecassis, M.M., Roberts, L.R., et al. (2018). Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases. *Hepatology*, 68(2), 723–750. <https://doi.org/10.1002/hep.29913>
- McGlynn, K.A., Petrick, J.L., El-Serag, H.B. (2021). Epidemiology of Hepatocellular Carcinoma. *Hepatology*, 73(Suppl 1), 4-13. DOI: 10.1002/hep.31288.

- Meriggi F., Graffeo M. (2021). Clinical Characterisation and Management of the Main Treatment – Induced Toxicities in Patients with Hepatocellular Carcinoma and Cirrhosis. *Cancers*,13(584), 1-19. Available from : 10.3390/cancers13030584
- Moawad,A.W., Fuentes,D., Khalaf,A.M., Blair,K.J., Szklaruk,J., Qayyum,A., Hazle J.D. (2020). Feasibility of Automated Volumetric Assessment of Large Hepatocellular Carcinomas’ Responses to Transarterial Chemoembolization. *Frontiers in Oncology*,572(10),1-10.doi: 10.3389/fonc.2020.00572
- Muthiah,M.D., & Sanyal,A.J. (2020). Burden of Disease due to Nonalcoholic Fatty Liver Disease. *Gastroenterology Clinics of North America*,49(1),1–23. <https://doi.org/10.1016/j.gtc.2019.09.007>
- Nadiroh,A. & Hariani,D. (2021). Efek Ekstrak Daun Pepaya Jepang terhadap Kadar Kolesterol, Morfometri, dan Histologi Hepar Mencit Hiperkolesterolemia. *LenteraBio : Berkala Ilmiah Biologi*, 11(1), 101–112.
- Osman M.F., Farag A.S.A., Samy H.A., et al. (2021). Role of Multislice Computed Tomography 3D Volumetric Analysis in the Assessment of the Therapeutic Response of Hepatocellular Carcinoma After Transarterial Chemoembolization. *Egyptian Journal of Radiology and Nuclear Medicine*,52(177),1-10. Available from : <https://ejrnm.springeropen.com/articles/10.1186/s43055-021-00542-w>
- Patel,T., Harnois,D. (2014). Assessment of Response to Therapy in Hepatocellular Carcinoma. *Annals of Medicine*,46,130-7. doi:10.3109/07853890.2014.891355.
- Qian,W., Gong,G., Su,H., Zhao,Y., Fu,W., Wang,Y., Ji,W., et al. (2023). Heparin-a-sensor-platform with hybridization chain reaction amplification strategy to intuitively monitor the hepatotoxicity of natural compounds. *Acta Biomaterialia*, 160, 73–86. Available from : <https://doi.org/10.1016/j.actbio.2023.02.021>

- Ramandhita,A.P. & Hanum,L. (2022). Efek Antikanker Nanopartikel Alginat Ekstrak Etanol Daun Sirsak (*Annona muricata* Linn) pada Kultur Sel Kanker Hepar (HepG2). *Jurnal Riset Kedokteran*,1(2),130–3. Available from : <https://doi.org/10.29313/jrk.v1i2.566>
- Raoul,J.-L., Forner,A., Bolondi,L., Cheung,T.T., Kloeckner,R., & de Baere,T. (2019). Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence. *Cancer Treatment Reviews*,72,28–36. Available from : <https://doi.org/10.1016/j.ctrv.2018.11.002>
- Samant,H., Amiri,H.S., Zibari,G.B. (2021). Addressing the worldwide hepatocellular carcinoma: epidemiology, prevention and management. *Journal of Gastrointestinal Oncology*,12(S2), S361–S373. Available from: <https://doi.org/10.21037/jgo.2020.02.08>
- Sakuraoka,Y., Kubota,K., Tanaka,G., Shimizu,T., Tago,K., Hwa,T.K., Matsumoto,T. (2020). Is Left-Sided Involvement of Hepatocellular Carcinoma an Important Preoperative Predictive Factor of Poor Outcome?. *World Journal of Surgical Oncology*,18(1),pp.1-9. doi: 10.1186/s12957-020-02100-6
- Sastroasmoro,S. & Ismael,S. (2011). Dasar-dasar Metodologi Penelitian Klinis. *Usulan Penelitian. In S. Sastroasmoro & S. Ismael, eds.* Jakarta:Sagung Seto,31-63.
- Sieghart,W., Huckle,F., & Peck-Radosavljevic,M. (2015). Transarterial chemoembolization: Modalities, indication, and patient selection. *Journal of Hepatology*,62(5),1187–95. <https://doi.org/10.1016/j.jhep.2015.02.010>
- Shin S.W. (2009). The Current Practice of Transarterial Chemoembolization for the Treatment of Hepatocellular Carcinoma. *Korean Journal of Radiology*,10(05),425. Available from :

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2731859/pdf/kjr-10-425.pdf>

Terzi,E., Golfieri,R., Piscaglia,F., Galassi,M., Dazzi,A., Leoni,S., Giampalma,E. (2012). Response rate and clinical outcome of HCC after first and repeated cTACE performed “on demand”. *Journal of Hepatology*, 57(6),1258–67. Available from : <https://doi.org/10.1016/j.jhep.2012.07.025>

Timaran Montenegro D.E., Ramirez C.A.T., Mateo Y.S., et al. (2020). CT-Based Hepatic Residual Volume and Predictors of Outcomes of Patients with Hepatocellular Carcinoma Unsuitable for Surgical Therapy Undergoing Transarterial Chemoembolization. *Academic Radiology*,27(6),807-14. doi : 10.1016/j.acra.2019.09.003.

Vemuri C.R., Jarecha R., Hwi K.K., et al. (2014). Importance of Volumetric Measurement Processes in Oncology Imaging Trials for Screening and Evaluation of Tumors as Per Response Evaluation Criteria in Solid Tumors. *Asian Pacific Journal of Cancer Prevention*,15,2375-8. Available from : http://journal.waocp.org/article_28930_f08478ebd05786ace031272142184ae3.pdf

Villanueva,A. (2019). Hepatocellular Carcinoma. *The New England Journal of Medicine*,380,1450-62.

Wan L., Dong DH., Wu X.N., Ding H.F., Lu Q., Yongtian, Zhang XF, et al. (2020). Single Large Nodule (>5cm) Prognosis in Hepatocellular Carcinoma : Kinship with Barcelona Clinic Liver Cancer (BCLC) Stage A or B?. *Medical Science Monitor*, 26, pp.e9267911 - e9267917.

World Health Organization (WHO). (2020). Indonesia. *Global Cancer Observatory (Globocon), International Agency for Research on Cancer*. Available from : <https://gco.iarc.fr/today/data/factsheets/populations/360-indonesia-fact-sheets.pdf>

Wible B.C. (2018). Diagnostic Imaging : Interventional Procedures. *Elsevier;Second Edition*, 588-99.

- Wu,ZJ., Xie,YF., Chang,X., Zhang,L., Wu,HY., Liu,JB., ZhangJX., et al. (2021). Type of Necrosis Influences Prognosis in Hepatocellular Carcinoma After the First Transarterial Chemoembolization. *Med Sci Monit*,27, e929884-1–e929884-10. doi: 10.12659/MSM.929884
- Xu,X., Chen,C., Liu,Q., & Huang,X. (2020). A Meta-analysis of TAE/TACE Versus Emergency Surgery in the Treatment of Ruptured HCC. *CardioVascular and Interventional Radiology*,43(9),1263–1276. Available from : <https://doi.org/10.1007/s00270-020-02514-5>
- Ye,S.L., Takayama,T., Geschwind,J., Marrero,J.A., Bronowicki,J.P. (2010). Current Approaches to the Treatment of Early Hepatocellular Carcinoma. *The Oncologist*,15 Supplement 4, pp,34-41. DOI: 10.1634/theoncologist.2010-S4-34
- Younossi, Z., Tacke, F., Arrese, M., Sharma, B.C., Mostafa, I., Bugianesi, E., Wai-Sun Wong, V., et al. (2019). Global Perspectives on Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis. *Hepatology*,69(6),2672–82. <https://doi.org/10.1002/hep.30251>
- Zhang J.W, Feng X.Y., Liu H.Q, et al. (2010). CT Volume Measurement for Prognostic Evaluation of Unresectable Hepatocellular Carcinoma After TACE. *World Journal of Gastroenterology*,16(16),2038-2045. doi :10.3748/wjg.v16.i16.2038.
- Zhong, B.-Y., Jin, Z.-C., Chen, J.-J., Zhu, H.-D., & Zhu, X.-L. (2023). Role of Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma. *Journal of Clinical and Translational Hepatology*,000(000),000–000. <https://doi.org/10.14218/JCTH.2022.00293>